No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Merck & Co., Inc. operates as a leading global healthcare enterprise. Its operations are structured into two primary segments: Pharmaceutical and Animal Health. The Pharmaceutical division is dedicated to offering human health solutions, encompassing prescription medicines for critical therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular health, and diabetes. This segment also provides a suite of vaccine products designed for preventive use across pediatric, adolescent, and adult populations. Conversely, the Animal Health segment is committed to the discovery, development, production, and commercialization of veterinary pharmaceuticals, vaccines, and comprehensive health management solutions. This also extends to sophisticated digitally connected products for identification, traceability, and monitoring of animals. The company's extensive customer base includes drug wholesalers, retail pharmacies, hospitals, and various governmental agencies. It also caters to managed health care providers, such as health maintenance organizations and pharmacy benefit managers, as well as individual physicians, physician distributors, veterinarians, and animal producers. Furthermore, Merck & Co., Inc. actively collaborates with several industry partners, including AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc., to jointly advance and bring to market long-acting treatments for HIV. Established in 1891, the company maintains its corporate headquarters in Kenilworth, New Jersey.
www.merck.comNo one on the platform currently holds 6MK.DE.
No tracked institution reports a position in 6MK.DE as of their last filing.
No one on the platform has traded 6MK.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 26.0% | 17.4% | 14.2% | — | — | — |
| Rev. Growth % | 1.3% | 6.3% | ||||
| Profit Margin % | 28.1% | 21.3% | 17.8% | |||
| Free Cash Flow Margin % | 19.0% | 21.4% | 19.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $66.2B | +2.1% | $2.71 | $2.64–$2.77 | — | 1 |
| 2027 | $69.2B | +4.6% | $9.41 | $9.17–$9.63 | — | 1 |
| 2028 | $73.3B | +6.0% | $10.40 | $10.13–$10.64 | — | 1 |
| 2029 | $73.6B | +0.4% | $10.18 | $9.92–$10.42 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-0.24 | $-0.11 | +51.9% |
| 2026-04-30 | $-1.28 | $-1.11 | +13.2% |
| 2026-02-03 | $1.71 | $1.74 | +1.8% |
| 2025-10-30 | $2.01 | $1.98 | -1.5% |
| 2025-07-29 | $1.73 | $1.50 | -13.3% |
| 2025-04-24 | $1.97 | $1.83 | -7.1% |
| 2025-02-04 | $1.55 | $1.42 | -8.4% |
| 2024-10-31 | $1.33 |
| $1.13 |
| -15.0% |
| +0.06% |
| $156.7B |
| — |
| NOV.DENovo Nordisk A/S | $36.88 | -2.16% | $163.8B | — |
| PFE.DEPfizer Inc. | $23.86 | -0.81% | $136.0B | — |
Source: Financial Modeling Prep · peers by sector/industry